[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:myelodysplastic-myeloproliferative-neoplasm:receptor-type-tyrosine-protein-kinase-flt3":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Myelodysplastic\u002FMyeloproliferative Neoplasm","Receptor-Type Tyrosine-Protein Kinase FLT3",3,[8,16,23],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07270978","Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS",[12],"Phase 1","RECRUITING","2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.951482Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04140487","Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent\u002FRefractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome\u002FMyeloproliferative Neoplasm",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:31.164304Z","2026-04-29T02:57:57.109829Z",{"nct_id":24,"title":25,"phases":26,"status":27,"updated_at":28,"content_modified":29},"NCT04493138","Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic\u002FMyeloproliferative Neoplasm With FLT3 or CBL Mutations",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T02:33:22.894436Z","2026-05-05T02:43:28.119922Z"]